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Background: Heparin inhibits the activity of factors Xa and IIa in the blood coagulation cascade.
Results: A series of size-defined N-sulfated oligosaccharides were synthesized to probe the size requirement for the oligosac-
charides displaying anti-IIa activity.
Conclusion:Oligosaccharides that display anti-IIa activity are longer than 19 saccharide residues.
Significance: The results will direct efforts to prepare synthetic heparin with both anti-Xa and anti-IIa activities.
Heparan sulfate (HS) and heparin are highly sulfated polysac-
charides. Heparin is a commonly used anticoagulant drug that
inhibits the activities of factorsXa and IIa (also knownas throm-
bin) to prevent blood clot formation. Here, we report the syn-
thesis of a series of size-defined oligosaccharides to probe the
minimum size requirement for an oligosaccharide with anti-IIa
activity. The synthesis was completed by a chemoenzymatic
approach involving glycosyltransferases, HS sulfotransferases,
and C5-epimerase. We demonstrate the ability to synthesize
highly purifiedN-sulfo-oligosaccharides havingup to21 saccha-
ride residues. The results from anti-Xa and anti-IIa activity
measurements revealed that an oligosaccharide longer than 19
saccharide residues is necessary to display anti-IIa activity. The
oligosaccharides also exhibit low binding toward platelet fac-
tor 4, raising the possibility of preparing a synthetic heparin
with a reduced effect of heparin-induced thrombocytopenia.
The results from this study demonstrate the ability to synthe-
size large HS oligosaccharides and provide a unique tool to
probe the structure and function relationships of HS that
require the use of large HS fragments.
Heparan sulfate (HS)2 is a highly sulfated polysaccharide that
is widely expressed on the mammalian cell surface and in the
extracellularmatrix.HS is involved in regulating numerous bio-
logical processes such as blood coagulation, embryonic devel-
opment, inflammatory responses, and assisting viral/bacterial
infections (1). The disaccharide-building block for HS consists
of GlcUA or IdoUA and glucosamine, each of which is capable
of carrying sulfo groups. The position of the sulfo groups and
the location of the IdoUA units dictate the functions of HS (2).
The biosynthesis of HS occurs in the Golgi apparatus and
involves several specialized sulfotransferases, glycosyltrans-
ferases, and an epimerase (3). HS polymerase, known as EXT-1
and EXT-2, is responsible for building the polysaccharide back-
bone, containing repeating units of -GlcUA-GlcNAc-. The
backbone is then modified by N-deacetylase/N-sulfotrans-
ferase (which has two separate domains displaying the activity
of N-deacetylase and N-sulfotransferase, respectively), C5-epi-
merase (which converts GlcUA to IdoUA), 2-O-sulfotrans-
ferase, 6-O-sulfotransferase, and 3-O-sulfotransferase to pro-
duce HS.
Heparin, a commonly used anticoagulant drug, is a special-
ized formofHSwith higher levels of sulfation and IdoUA. It has
remained as a top choice for treating thrombotic disorders for
50 years. Heparin achieves its anticoagulant activity by form-
ing a 1:1 complex with antithrombin (AT). The resultant AT-
heparin complex inhibits a series of proteases in the blood coag-
ulation cascade, including factor Xa and thrombin (or factor
IIa), to prevent the formation of blood clots. The heparin-ex-
erting Xa inhibition effect requires the presence of a pentasac-
charide domain with the structure of -GlcNAc6S-GlcUA-
GlcNS3S6S-IdoUA2S-GlcNS6S-, whereas the inhibition of
IIa requires oligosaccharides larger than tetradecasaccharides
(14-mer); the precise structures for oligosaccharides with anti-
IIa activity are unknown (4, 5).
Heparin is currently isolated from porcine intestine or
bovine lung through a poorly regulated supply chain. The
worldwide distribution of contaminated heparin in 2007 raised
concern over the safety and reliability of animal-sourced hepa-
rins (6, 7). A cost-effectivemethod for preparing synthetic hep-
arin and securing the safety of the heparin supply chain is highly
desirable. Although heparin and HS fragments can be synthe-
sized by a purely chemical method (8, 9), this synthesis is
extremely challenging, especially for products larger than an
octasaccharide. A new chemoenzymatic approach provides a
promising alternative method to synthesize polysaccharides
and structurally defined oligosaccharides (10–14).
In this work, we attempted to synthesize oligosaccharides
with anti-IIa activity using the chemoenzymatic approach. A
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series of size-defined N-sulfo-oligosaccharides were synthe-
sized using bacterial glycosyltransferase, an unnatural UDP-
sugar, and N-sulfotransferase with high efficiency and purity.
We demonstrate for the first time the preparation of oligosac-
charides with up to 21 saccharide residues.We converted these
N-sulfo-oligosaccharides to O-sulfated oligosaccharides to
measure their anti-Xa and anti-IIa activities. Our data suggest
that the minimum size for the oligosaccharides to present anti-
IIa activity is 19 residues long and that a size of 21 saccharide
residues is required to display full anti-IIa activity. The results
will assist our long-term efforts to prepare synthetic heparin
and HS with desired biological activities and structural
controls.
EXPERIMENTAL PROCEDURES
Expression of HS Biosynthetic Enzymes—A total of eight
enzymes were used for the synthesis, including N-sulfotrans-
ferase, C5-epimerase, 2-O-sulfotransferase (2-OST), 6-OST-1,
6-OST-3, 3-OST-1, KfiA, and Pasteurellamultocida heparosan
synthase 2 (pmHS2). All enzymeswere expressed inEscherichia
coli and purified by appropriate affinity chromatography as
described previously (13).
Preparation of Enzyme Cofactors—A sulfo donor, 3-phos-
phoadenosine 5-phosphosulfate (PAPS), was prepared
using adenosine phosphokinase and ATP-sulfurylase (13).
The preparation of UDP-N-trifluoroacetylglucosamine
(GlcNTFA) was started from glucosamine (Sigma), which
was first converted to GlcNTFA by reacting with S-ethyl
trifluorothioacetate (Sigma) following the protocol
described previously (13). The resultant GlcNTFA was con-
verted to GlcNTFA 1-phosphate using N-acetylhexosamine
1-kinase (15). The plasmid expressing N-acetylhexosamine
1-kinase was a generous gift from Prof. Peng Wang (Georgia
State University), and the expression of the enzyme was car-
ried out in E. coli as reported (15). The UDP-GlcNTFA syn-
thesis was completed by transforming GlcNTFA 1-phos-
phate using glucosamine-1-phosphate acetyltransferase/N-
acetylglucosamine-1-phosphate uridyltransferase (GlmU) as
described (13). The resultant UDP-GlcNTFA was then ready
for the elongation reaction using KfiA as described below.
Preparation of Oligosaccharide Backbone—A disaccharide
(GlcUA-anhydromannitol (AnMan)) was prepared from hepa-
rosan as described (13). The disaccharide was then elongated to
N-trifluoroacetylated (N-TFA) oligosaccharides by repetitive
exposure toKfiA, pmHS2,UDP-GlcNTFA, andUDP-GlcUA as
shown in Fig. 1. Briefly, the disaccharide (20 mg), KfiA (30
g/ml), and UDP-GlcNTFA (500 M) were mixed in 120 ml of
50 mM Tris buffer. The reaction was incubated overnight at
room temperature. The completion of the reaction was moni-
tored by the disappearance of UDP-GlcNTFA using a silica-
based polyamine HPLC column (Waters). Once the reaction
was completed, pmHS2 (30 g/ml) and UDP-GlcUA (750 M)
were added, and the reaction was incubated for another 24 h at
room temperature. The resultant product was a tetrasaccha-
ride, which was purified using a Bio-Gel P-2 column (0.75 
200 cm) that was equilibrated with 0.1 M ammonium bicarbon-
ate at a flow rate of 6ml/h. The fractions were then subjected to
electrospray ionization (ESI) MS analysis. The fractions con-
taining the tetrasaccharide were pooled. The procedures for
synthesizing theN-TFApentadecasaccharide (15-mer),N-TFA
heptadecasaccharide (17-mer), N-TFA nonadecasaccharide
(19-mer), andN-TFAhenicosasaccharide (21-mer) were essen-
tially the same, completed by repeating the above cycle with the
designated times.
When the backbone was elongated beyond octasaccharide, a
special method was employed to deplete UDP-GlcNTFA and
UDP-GlcNAc prior to further elongation by pmHS2. If unre-
acted UDP-GlcNTFA or UDP-GlcNAc was present in the
GlcUA elongation step involving pmHS2, an uncontrolled
elongation occurred, resulting in a mixture. It was therefore
especially important to avoid the formation of mixtures when
the synthesis reached octasaccharide and beyond because the
P-2 column cannot separate oligosaccharides larger than
octasaccharides. To this end, the disaccharide GlcUA-AnMan
was added to the reaction to exhaust the residual UDP-
GlcNTFA and GlcNAc at the reaction, and the resultant trisac-
charide was removed using the P-2 column.
N-Detrifluoroacetylation—Oligosaccharide backbones (1–2
mg) were resuspended in solution (20 ml) containing 2:2:1
(v/v/v) CH3OH, H2O, and (C2H5)3N. The reaction was incu-
bated overnight at 50 °C. The samples were dried and reconsti-
tuted in H2O to recover de-N-TFA oligosaccharides.
N-Sulfation of Oligosaccharides—N-Sulfation of oligosac-
charides was carried out by incubating the oligosaccharide sub-
strates with N-sulfotransferase and PAPS. The reaction mix-
ture typically contained 1–2 mg of de-N-TFA oligosaccharide,
500 M PAPS, 50 mM MES (pH 7.0), and 1 mg of N-sulfotrans-
ferase in a total volume of 15 ml. The reaction mixture was
incubated overnight at 37 °C.
Sulfation and Epimerization Modifications of Oligosaccha-
ride Backbones—The conversion of N-sulfo-oligosaccharides
to the final products involved three steps, including C5-epimer-
ization/2-O-sulfation, 6-O-sulfation, and 3-O-sulfation. N-
Sulfo-oligosaccharides (1–2 mg) were incubated in a reaction
mixture containing 50 mM MES (pH 7.0), 0.03 mg/ml C5-epi-
merase, and 2 mM CaCl2 in a total volume of 40 ml. After incu-
bation for 30 min at 37 °C, 2-OST (0.03 mg/ml) and 200 M
PAPS were added, and the reaction was incubated overnight at
37 °C. The products were purified using a DEAE column as
described previously (14). For 6-O-sulfation, the substrate was
incubated overnight at 37 °C in a reaction mixture containing
50 mM MES (pH 7.0) and 500 M PAPS in the presence of
6-OST-1 (0.03 mg/ml) and 6-OST-3 (0.03 mg/ml) in a total
volume of 20 ml. The products were purified using a DEAE
column. For 3-O-sulfation, the substrate was incubated over-
night at 37 °C in a reaction mixture containing 3-OST-1 (0.03
mg/ml), 10mMMnCl2, 5mMMgCl2, and 500MPAPS in a total
volume of 20 ml.
MS Analysis of Oligosaccharides—Analyses were performed
with a Thermo Scientific LCQ-Deca system. The non-sulfated
oligosaccharide (1 l) eluted from Bio-Gel P-2 column was
directly diluted in 200 l of 9:1 MeOH/H2O. A syringe pump
(Harvard Apparatus) was used to introduce the sample via
direct infusion (35 l/min). Experiments were carried out in
negative ionization mode with the electrospray source set to 5
kV and 275 °C. The sulfated oligosaccharide (1 l) was diluted
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in a different working solution containing 200 l of 70% aceto-
nitrile and 10mM imidazole. Experiments for sulfated oligosac-
charides were carried out in negative ionization mode with the
electrospray source set to 2 kV and 200 °C. The automatic gain
control was set to 1  107 for full-scan MS. The MS data were
acquired and processed using Xcalibur 1.3.
Inhibition of Factor Xa and IIa Activities—Assays were based
on a previously published method (16, 17). Briefly, factor Xa
(EnzymeResearch Laboratories, South Bend, IN) and thrombin
(Sigma) were diluted at 80 and 100 nM, respectively, with PBS
containing 1 mg/ml BSA. Human AT (Cutter Biological) was
diluted with PBS containing 1 mg/ml BSA to give a stock solu-
tion at a concentration of 0.4 M. The chromogenic substrates
S-2765 (for factor Xa assay) and S-2238 (for factor IIa assay)
were prepared at 1.3 and 1.5 mM in water. The synthesized
oligosaccharides or heparin was dissolved in PBS at various
concentrations (1–30 nM). The reaction mixture, which con-
sisted of 70l ofAT stock solution and 15l of sample solution,
was incubated at room temperature for 2 min. Factor Xa or
thrombin (10 l) was added. After incubation at room temper-
ature for 4min, 30l of S-2765 or S-2238was added. The initial
reaction rates as a function of concentration were used to cal-
culate the IC50 values. The absorbance of the reaction mixture
was measured at 405 nm continuously for 10 min. The absor-
bance values were plotted against the reaction time. The initial
reaction rates as a function of concentration were used to cal-
culate the IC50 values.
Binding of Oligosaccharides to Platelet Factor 4—A filter-
trapping assay was used to compare the binding of the different
oligosaccharides to platelet factor 4 (PF4) (18). The 35S-labeled
oligosaccharides (6000 cpm) were incubated with 0–15
g/ml PF4 in 50mMTris and 250mMNaCl (pH 7.3) for 30 min
at 37 °C to allow complex formation. The mixture was then
spotted onto a nitrocellulose membrane, which binds to pro-
teins nonspecifically, allowing the capture of complexes of PF4
and 35S-labeled oligosaccharide. The membrane wells were
washed with buffer and excised, and the bound radioactivity
was quantified using a scintillation counter.
Neutralizing Effect of PF4 on Anti-Xa Activity of Heparin and
Oligosaccharide—HS oligosaccharides were incubated in a
96-well plate with 70 l of BSA (1 mg/ml in PBS), 10 l of AT
(0.2 mg/ml in PBS), and 0–16 l of PF4 (0.45 mg/ml) for 2 min
at room temperature. Ten microliters of Xa was then added,
and after 4 min, 30 l of chromogenic substrate S-2765 (1
mg/ml) was added to initiate the color change reaction.
Sequential absorbance readings at 405 nm were started imme-
diately using a Bio-Tek ELx808 plate reader. The rate of
increased absorbance relative to the rate of a control sample
was used to define Xa activity. Quantities of oligosaccharides
showing 8% Xa activity in the absence of PF4 were used.
HPLC Analysis—Both DEAE-HPLC and polyamine-based
anion exchange HPLCwere used to determine the purity of the
oligosaccharides. The elution conditions for the HPLC analysis
have been described elsewhere (13).
Disaccharide Analysis of 35S-Labeled Oligosaccharides—The
35S-labeled compound was deacetylated and degraded with
nitrous acid at pH 4.5 and then at pH 1.5, followed by reduction
with sodium borohydride as described by Shively and Conrad
(19). The resultant 35S-labeled disaccharides were resolved
using a C18 reverse-phase column (0.46  25 cm; Vydac) under
reverse-phase ion-pairing HPLC conditions. The identities of
the disaccharides were determined by co-elution with the
appropriate 35S-labeled disaccharide standards.
RESULTS
Chemoenzymatic Synthesis of N-Sulfo-oligosaccharide Back-
bones—Although a pentasaccharide is sufficiently large to
exhibit anti-Xa activity (4), amuch longer heparin is required to
carry anti-IIa activity (5). The architecture of the IIa inhibitor is
believed to contain a domain that binds to AT, a domain that
binds to IIa, and a linker domain consisting of low sulfated (or
non-sulfated) -GlcUA-GlcNAc- repeating units (Fig. 1) (20).
Our first step toward the synthesis of HS oligosaccharides car-
rying anti-IIa activity involved synthesizing the oligosaccharide
backbonewith specificN-sulfo distribution. This uniqueN-sul-
fation pattern permitted the subsequent C5-epimerization and
O-sulfations to yield products with three segments: an
AT-binding domain, a linker domain, and a thrombin-binding
domain (as shown in Fig. 1). The synthesis was initiated from a
disaccharide, which was elongated to the desired size using two
bacterial glycosyltransferases,N-acetylglucosamine transferase
from E. coli strain K5 (KfiA) and pmHS2 (14). During the syn-
thesis, GlcNTFA residueswere strategically introduced into the
backbone, where the AT-binding and IIa-binding domains are
located, as the N-TFA group is readily converted to an N-sulfo
group by a chemoenzymatic approach. The linker region con-
tains GlcNAc residues.
A total of four N-TFA oligosaccharides were synthesized
from a decasaccharide designated as the “AT-binding site and
linker backbone” (Fig. 1). The structural difference in the four
N-TFA oligosaccharides was that each oligosaccharide con-
tained distinct numbers of the -GlcUA-GlcNTFA- repeating
unit in the IIa-binding domain. It should be noted that all four
compounds contain very similar structures in the AT-binding
and linker domains. The size of the -GlcUA-GlcNTFA- repeat-
ing unit was controlled by the cycles of modifications using
KfiA and pmHS2. For example, the preparation of the N-TFA
pentadecasaccharide (15-mer) involved five enzymatic steps
(three KfiA modification steps and two pmHS2 modification
steps), whereas the synthesis of theN-TFA henicosasaccharide
(21-mer) required 11 enzymatic steps (six KfiA modification
steps and five pmHS2 modification steps). The N-TFA oligo-
saccharides were synthesized in milligram scales.
The N-TFA oligosaccharides were next converted to
N-sulfo-oligosaccharides in two steps: alkaline detrifluoro-
acetylation and treatment withN-sulfotransferase. To this end,
four N-sulfated oligosaccharides, ranging from pentadeca- to
henicosasaccharides (1-4), were obtained. The purity of the
N-sulfation products was analyzed by high resolution DEAE-
HPLC analysis, and their molecular weights were determined
by ESI-MS. As shown in Fig. 2A, the 35S-labeled N-sulfo-heni-
cosasaccharide (4) was eluted in a predominant single symmet-
ric peak, suggesting that the compound is substantially pure.
The results of the ESI-MS analysis revealed the molecular
weight of Compound 4 to be 4263.2  1.0, very close to the
calculated value of 4261.5, suggesting that Compound 4 is a
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henicosasaccharide carrying eight sulfo groups (Fig. 2B and
Table 1). We completed the purity analysis using DEAE-HPLC
and molecular weight determination using ESI analysis (supple-
mental Figs. S1–S3) for Compounds 1-3. All of theseN-sulfo-oli-
gosaccharideshad theanticipatedmolecularweights (Table1) and
displayed high purity. Our data suggest that we obtained the
expected products.
Preparation of Oligosaccharides Carrying IdoUA Residues
and O-Sulfations—Incubation of N-sulfo-oligosaccharides
with C5-epimerase, 2-OST, 6-OST, and 3-OST yielded oligo-
FIGURE 1. Schematic synthesis of HS oligosaccharides. The synthesis was initiated from a disaccharide. The disaccharide was first elongated to an octasa-
ccharide to yield the AT-binding site backbone and then converted to a decasaccharide to yield the AT-binding site and linker backbone. Depending on the
structures of the final product, the elongation step was repeated several times to yield N-TFA oligosaccharides. The conversion of N-TFA oligosaccharides to
N-sulfo-oligosaccharides (1-4) was completed by two steps, including alkaline detrifluoroacetylation and N-sulfation. The resultant N-sulfo-oligosaccharides
were then modified sequentially by C5-epimerase, 2-OST, 6-OST, and 3-OST to form O-sulfated oligosaccharides (5-8).
FIGURE 2. Purity and structural analyses of the N-sulfo-henicosasaccharide (4, 21-mer). A, DEAE-HPLC elution profile of the 35S-labeled N-sulfo-henico-
sasaccharide. B, ESI-MS spectrum of the N-sulfo-henicosasaccharide. The chemical structure of the N-sulfo-henicosasaccharide is shown at beneath A and B.
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saccharides containing IdoUA and 2-O-, 6-O-, and 3-O-sulfa-
tions (Fig. 1). Unlike theN-sulfo-oligosaccharides, a mixture of
oligosaccharides was obtained after O-sulfations and C5-epi-
merization (9). We observed that the products were eluted as a
broad peak onDEAE-HPLC (supplemental Fig. S4). The result-
ant mixture is largely due to the incomplete modifications at
the epimerization and 2-O-sulfation steps. In addition, the
C5-epimerization reactions are likely to be reversible, making
the control of the placement of IdoUA and 2-O-sulfation in
these large oligosaccharides very difficult. A recent study dem-
onstrated that C5-epimerase displays both reversible and irre-
versible catalytic modes (21). It is apparent that C5-epimerase
recognizes the N-sulfation patterns of the polysaccharide sub-
strates to control the location/placement of IdoUA residues.
The full biological implications of the biphasic catalytic mode
of C5-epimerase are currently unknown.
Structural characterization of Compounds 5-8 was com-
pleted by disaccharide analyses (Tables 2 and 3). These oligo-
saccharides were 35S-labeled at 2-O-sulfo, 6-O-sulfo, and 3-O-
sulfo groups. To more accurately examine the compositions of
the products, two approaches were used to degrade the oligo-
saccharides to disaccharides, including heparin lyase degrada-
tion and nitrous acid degradation (Tables 2 and 3). Prior to the
3-O-sulfation step, these oligosaccharideswere subjected to the
heparin lyase degradation. Based on the specific 35S radioactiv-
ity of [35S]PAPS, we estimated that the O-sulfation levels in
these compounds (prior to 3-O-sulfation) were in the range of
1.2–1.5 O-sulfo groups (Table 2). The results from the disac-
charide analysis (Table 2) confirmed the estimatedO-sulfation
levels.
In the second disaccharide approach, nitrous acid was used
to degrade Compounds 5-8. The nitrous acid degradation
approach is necessary for analyzing Compounds 5-8 because
they contain 3-O-sulfated glucosamine residues that lead to
resistance to heparin lyase degradation (22). The results of
disaccharide analysis are presented in Table 3. It should be
noted that the compositions of the disaccharides obtained by
lyase and nitrous acid degradation are largely consistent.
The presence of monosaccharide in the nonreducing ends of
Compounds 5-8 was also demonstrated. Heparin lyase-de-
graded Compounds 5-8 were analyzed using Bio-Gel P-2. The
elution profiles of the degraded oligosaccharides from the Bio-
Gel P-2 column show the presence of 35S-labeled monosaccha-
ride, suggesting that these oligosaccharides have a GlcNS6S
residue at the nonreducing end (supplemental Fig. S5).
Determinations of Anti-Xa and Anti-IIa Activities of
Oligosaccharides—All anticoagulant HS structures exhibiting
anti-Xa and anti-IIa activities bind to AT. Indeed, an analysis
using affinity co-electrophoresis demonstrated that Com-
pounds 5-8 bound to AT effectively (supplemental Fig. S6).We
next determined the anti-Xa and anti-IIa activities. Both
anti-Xa and anti-IIa activities were measured using specific
chromogenic substrates (17). As expected, all four O-sulfated
oligosaccharides displayed anti-Xa activity with a similar
potency to heparin as well as the previously synthesized ultra
low molecular weight (ULMW) heparin 1 (14) (Fig. 3A and
Table 4). The results suggest that anti-Xa activity is indepen-
dent of the size of the oligosaccharides. This conclusion is con-
sistent with previous findings, namely that theminimum size of
the HS oligosaccharide with anti-Xa activity is a pentasaccha-
ride (5). In stark contrast, the anti-IIa activity measurement
revealed a dependence on the size of the oligosaccharide. The
oligosaccharides shorter than a heptadecasaccharide did not
exhibit detectable anti-IIa activity (Table 4). The nonadecasac-
charide (7, 19-mer) began to show weak anti-IIa activity (the
TABLE 1
Summary of the analysis of N-sulfo-oligosaccharides by MS
Compound Name Abbreviated structure
Mr
Calculated Measured
1 N-Sulfo-pentadecasaccharide (15-mer) GlcNS-(GlcUA-GlcNS)2-(GlcUA-GlcNAc)2-(GlcUA-GlcNS)2-GlcUA-AnMan 3009.5 3010.5  1.1
2 N-Sulfo-heptadecasaccharide (17-mer) GlcNS-(GlcUA-GlcNS)3-(GlcUA-GlcNAc)2-(GlcUA-GlcNS)2-GlcUA-AnMan 3426.8 3428.1  1.0
3 N-Sulfo-nonadecasaccharide (19-mer) GlcNS-(GlcUA-GlcNS)4-(GlcUA-GlcNAc)2-(GlcUA-GlcNS)2-GlcUA-AnMan 3844.2 3846.2  1.2
4 N-Sulfo-henicosasaccharide (21-mer) GlcNS-(GlcUA-GlcNS)5-(GlcUA-GlcNAc)2-(GlcUA-GlcNS)2-GlcUA-AnMan 4261.5 4263.2  1.0
TABLE 2
Summary of disaccharide analysis of the 15–17-mers without 3-O-sulfation degraded by heparin lyases
Oligosaccharides were 35S-labeled at both the 2-O-sulfo and 6-O-sulfo positions. The oligosaccharides were then degraded with a mixture of heparin lyases I–III. The









UA-GlcNAc6S 30.9% 30.0% 24.3% 26.6%
UA-GlcNS6S 31.0% 27.0% 17.4% 35.6%
UA2S-GlcNS 1% 1% 1.5% 2.1%
UA2S-GlcNS6S 38.0% 43.0% 57.6% 35.6%
O-Sulfo group/disaccharidea 1.4 (1.2)b 1.5 (1.4) 1.5 (1.6) 1.5 (1.4)
a The number of O-sulfo groups per disaccharide was determined based on the specific 35S radioactivity of [35S]PAPS.
b The numbers given in parentheses are the values based on disaccharide analysis.
TABLE 3
Summary of disaccharide analysis of Compounds 5– 8 degraded by
nitrous acid
The disaccharides were produced by exposing the oligosaccharides (Compounds
5–8) to nitrous acid degradation at both pH 4.5 and 1.5. The resultant disaccharides









% % % %
GlcUA-AnMan6S 6.5 20.0 24.9 21.7
IdoUA-AnMan6S 21.8 21.2 21.8 16.9
IdoUA2S-AnMan 1 1 1 1
GlcUA-AnMan3S6S 26.1 19.6 19.4 16.0
IdoUA2S-AnMan6S 45.6 39.2 33.9 45.4
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anti-Xa/anti-IIa ratio was determined to be 1:5). The henico-
sasaccharide (8, 21-mer) showed stronger anti-IIa activity, with
an anti-Xa/anti-IIa ratio of 1:2 (Fig. 3B and Table 4). The anti-
Xa/anti-IIa ratio for heparin was 1:1 (Table 4). Our data suggest
that the oligosaccharides should be longer than 21 saccharide
units to fully exhibit both anti-Xa and anti-IIa activities com-
parable with those observed for heparin. In a previous report, a
synthetic heparin mimetic with a size larger than 16 saccharide
units was the minimum length for displaying anti-IIa activity
(20). Our data demonstrated a slightly larger oligosaccharide
for anti-IIa activity than reported previously for heparin. This
result is not completely unexpected given the fact that two sac-
charide units at the reducing end ofCompound8 are unlikely to
participate in binding to AT or IIa. Furthermore, a cluster of
highly sulfated glucose residueswas used tomimic the IIa-bind-
ing domain in the synthetic heparin mimetic due to the com-
plexity of the chemical synthesis process. In fact, highly sulfated
glucose residues are not present in heparin or HS isolated from
natural sources (3).
Determination of the Binding of Oligosaccharides to PF4—
PF4 is a positively charged chemokine. PF4 binds to heparin
avidly, and the resultant complex induces the production of
anti-PF4/heparin antibody, leading to a life-threatening throm-
botic disorder known as heparin-induced thrombocytopenia
(23). Thus, reducing the binding between heparin and PF4
could potentially decrease the risk of heparin-induced throm-
bocytopenia associated with the use of heparin. To this end, we
tested the binding of the oligosaccharides and PF4. Although all
compounds bound to PF4, the oligosaccharides bound to PF4
to a lower extent compared with full-length HS (Fig. 4A). It
should be noted that ULMW heparin 1 did not bind to PF4,
consistent with the previous finding indicating that the mini-
mum size of HS oligosaccharides that bind to PF4 is an octasa-
ccharide (24, 25). Furthermore, the use of fondaparinux, a syn-
thetic ULMW heparin, effectively eliminates the risk of
heparin-induced thrombocytopenia (26, 27).
Next, we compared the binding affinity between O-sulfated
oligosaccharides and full-length heparin using a PF4 neutral-
ization assay (24). In this experiment, heparin and O-sulfated
oligosaccharides were incubated with AT and Xa. Under these
conditions, the activity of Xa is low because of the presence of
AT-saccharide complexes. Upon the addition of PF4 to the
reactionmixture, PF4 displaced AT by interacting with the sac-
charides. Consequently, AT lost the ability to inhibit the activ-
ity of Xa. As shown in Fig. 4B, PF4 effectively neutralized the
inhibition effect of heparin at an ED50 of 1.2 g/ml. In con-
trast, Compound 8 displayed a much higher ED50 (3.4 g/ml),
suggesting that the synthesized O-sulfo-henicosasaccharide
has reduced binding affinity for PF4. As expected, PF4 was
unable to neutralize the anti-Xa activity of ULMW heparin 1
because ULMW heparin 1 does not bind to PF4 (Fig. 4B).
DISCUSSION
In this study, we have reported the synthesis of large HS
oligosaccharides that display anti-IIa activity. Although HS
inhibits the activities ofXa and IIa through interactionwithAT,
the HS domain that exhibits anti-IIa activity is 3–4 times
longer than the domain that exhibits anti-Xa activity. To date,
the synthesis of genuine HS oligosaccharides with both anti-Xa
and anti-IIa activities had not been accomplished for the fol-
FIGURE 3. Determination of the anti-Xa and anti-IIa activities of O-sulfated oligosaccharides. A, anti-Xa activity using a chromogenic substrate. Com-
pounds 5 and 8 and heparin were incubated with AT, Xa, and the peptide substrate S-2765. The activity of Xa was determined by the rate of increase in the
absorbance at 405 nm. The activity without drugs was defined as 100%. Each data point represents the mean  S.D. of three determinations. Additional data
for the anti-Xa activities of other compounds are shown in Table 4. B, anti-IIa activity using a chromogenic substrate. Compounds 7 and 8 and heparin were
incubated with AT, IIa, and the peptide substrate S-2238. The activity of IIa was determined by the rate of increase in the absorbance at 405 nm. The activity
without drugs was defined as 100%. Each data point represents the mean  S.D. of three determinations.
TABLE 4
Inhibition of anti-Xa and anti-IIa by O-sulfated oligosaccharides
IC50 represents the half-maximum inhibitory concentration. ND, not detectable;
NA, not applicable.
Compound
IC50 Ratio of anti-Xa
to anti-IIaAnti-Xa Anti-IIa
nM
ULMW heparin 1a 2.8 ND NA
9 1.2 ND NA
10 1.5 ND NA
11 0.8 4.2 1:5
12 1.0 1.7 1:1.7
Heparin 0.7 0.7 1:1
a ULMW heparin 1 is a heptasaccharide using a chemoenzymatic approach with a
structure of GlcNAc6S-GlcUA-GlcNS3S6S-IdoUA2S-GlcNS6S-GlcUA-AnMan
(14).
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lowing reasons. First, the chemical synthesis is extremely diffi-
cult if not impossible because of the large size. Second, the
precise structure of the HS oligosaccharide that displays both
anti-Xa and anti-IIa activities is unknown. Previously, we dem-
onstrated the synthesis of polysaccharides using HS biosyn-
thetic enzymes and a capsular polysaccharide from the E. coli
K5 strain; however, the products are amixture differing in both
the size and distribution of sulfo groups and IdoUA residues,
known as sulfation patterns (10, 12). In addition, we completed
the synthesis of size- and sulfation pattern-defined ULMW
heparins; however, the products exhibit only anti-Xa activity
because of their short size (14). Here, we implemented the che-
moenzymatic approach to synthesize size-defined oligosaccha-
rides displaying both anti-Xa and anti-IIa activities. Although
the products are heterogeneous in sulfation patterns, this effort
represents a step forward in controlling the synthesis of heparin
drugs.
The chemical synthesis of heparin-like oligosaccharides with
anti-IIa activity has been completed by Petitou et al. (20). In this
impressive piece of work, a series of oligosaccharides up to an
icosasaccharide (20-mer) were synthesized. However, none
were authentic HS oligosaccharides, but rather heparinmimet-
ics. The IIa-binding domain in these compounds consists of
methylated glucose sulfate residues, an unnatural saccharide, to
reduce the complexity of the synthesis. These compounds,
especially a hexadecasaccharide (16-mer), showed very prom-
ising anticoagulant activity in vitro and in vivo, with the possi-
bility to become a newgeneration of synthetic heparin (28). The
hexadecasaccharide was also used in crystal structural studies
of the ternary complex of AT-thrombin (factor IIa)-heparin to
understand the mechanism of action of the heparin-mediated
deactivation of IIa (29, 30). Unfortunately, the hexadecasaccha-
ride reportedly failed in a recent clinical trial due to excessive
bleeding effects (31).
Unlike chemical synthesis, the chemoenzymatic approach
produces authentic heparin molecules and involves a much
shorter synthetic route. Although we were unable to synthesize
structurally homogeneous O-sulfated oligosaccharides in this
study, the results clearly show that this approach can be used to
prepare N-sulfo-oligosaccharides up to 21 saccharide residues.
The availability of theseN-sulfo-oligosaccharides permitted us
to probe the size requirement for oligosaccharides with anti-IIa
activity. We believe that the structural heterogeneity stemmed
from themodification steps using C5-epimerase and 2-O-sulfa-
tion because we have demonstrated the synthesis of a structur-
ally pure dodecasaccharide carrying bothN-sulfation and 6-O-
sulfation in a previously published report (13). Further
investigation into the control of the placement of IdoUA2S res-
idues is needed to synthesize large heparin oligosaccharides
carrying IdoUA2S residues.
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